The milestone-based licensing deal includes a $29m investment up front and could be worth more than $400m to the small molecule technology developer.
Canada-based biopharmaceutical company Resverlogix signed a framework licensing agreement with pharmaceutical company Shenzhen Hepalink Pharmaceutical on Monday that included C$35m ($29.1m) in equity funding.
Dependent on sales milestones and royalty payments, the deal could eventually be worth more than $400m. Hepalink made the equity investment in the form of a common share purchase.
The deal also includes a $12.4m equity investment by Eastern Capital, an investment vehicle for businessman Kenneth Dart, which is subject to the Hepalink investment closing. The…
